Suppr超能文献

GAB2通过促进SHP2/MYCN合作在神经母细胞瘤发病机制中起关键作用。

Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation.

作者信息

Zhang Xiaoling, Dong Zhiwei, Zhang Cheng, Ung Choong Yong, He Shuning, Tao Ting, Oliveira Andre M, Meves Alexander, Ji Baoan, Look A Thomas, Li Hu, Neel Benjamin G, Zhu Shizhen

机构信息

Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Mayo Clinic Cancer Center, Rochester, MN 55902, USA.

Department of Molecular Pharmacology and Experimental Therapeutics, Center for Individualized Medicine, Mayo Clinic College of Medicine, Rochester, MN 55902, USA.

出版信息

Cell Rep. 2017 Mar 21;18(12):2932-2942. doi: 10.1016/j.celrep.2017.02.065.

Abstract

Growing evidence suggests a major role for Src-homology-2-domain-containing phosphatase 2 (SHP2/PTPN11) in MYCN-driven high-risk neuroblastoma, although biologic confirmation and a plausible mechanism for this contribution are lacking. Using a zebrafish model of MYCN-overexpressing neuroblastoma, we demonstrate that mutant ptpn11 expression in the adrenal gland analog of MYCN transgenic fish promotes the proliferation of hyperplastic neuroblasts, accelerates neuroblastomagenesis, and increases tumor penetrance. We identify a similar mechanism in tumors with wild-type ptpn11 and dysregulated Gab2, which encodes a Shp2 activator that is overexpressed in human neuroblastomas. In MYCN transgenic fish, Gab2 overexpression activated the Shp2-Ras-Erk pathway, enhanced neuroblastoma induction, and increased tumor penetrance. We conclude that MYCN cooperates with either GAB2-activated or mutant SHP2 in human neuroblastomagenesis. Our findings further suggest that combined inhibition of MYCN and the SHP2-RAS-ERK pathway could provide effective targeted therapy for high-risk neuroblastoma patients with MYCN amplification and aberrant SHP2 activation.

摘要

越来越多的证据表明,含Src同源2结构域的磷酸酶2(SHP2/PTPN11)在MYCN驱动的高危神经母细胞瘤中起主要作用,尽管缺乏生物学证实以及对此作用的合理机制。利用MYCN过表达神经母细胞瘤的斑马鱼模型,我们证明在MYCN转基因鱼的肾上腺类似物中突变型ptpn11的表达促进了增生性神经母细胞的增殖,加速了神经母细胞瘤的发生,并增加了肿瘤发生率。我们在具有野生型ptpn11和失调的Gab2的肿瘤中发现了类似机制,Gab2编码一种在人类神经母细胞瘤中过表达的Shp2激活剂。在MYCN转基因鱼中,Gab2过表达激活了Shp2-Ras-Erk途径,增强了神经母细胞瘤的诱导,并增加了肿瘤发生率。我们得出结论,在人类神经母细胞瘤发生过程中,MYCN与GAB2激活的或突变的SHP2协同作用。我们的研究结果进一步表明,联合抑制MYCN和SHP2-RAS-ERK途径可为具有MYCN扩增和异常SHP2激活的高危神经母细胞瘤患者提供有效的靶向治疗。

相似文献

8
GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma.GAS7 缺乏促进 MYCN 驱动的神经母细胞瘤转移。
Cancer Res. 2021 Jun 1;81(11):2995-3007. doi: 10.1158/0008-5472.CAN-20-1890. Epub 2021 Feb 18.

引用本文的文献

本文引用的文献

8
Neuroblastoma: molecular pathogenesis and therapy.神经母细胞瘤:分子发病机制与治疗
Annu Rev Med. 2015;66:49-63. doi: 10.1146/annurev-med-011514-023121. Epub 2014 Oct 27.
9
Mechanisms of neuroblastoma regression.神经母细胞瘤消退的机制。
Nat Rev Clin Oncol. 2014 Dec;11(12):704-13. doi: 10.1038/nrclinonc.2014.168. Epub 2014 Oct 21.
10
Targeting MYCN in neuroblastoma by BET bromodomain inhibition.通过 BET 溴结构域抑制靶向神经母细胞瘤中的 MYCN。
Cancer Discov. 2013 Mar;3(3):308-23. doi: 10.1158/2159-8290.CD-12-0418. Epub 2013 Feb 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验